Promacta ® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low platelet ...
Updates related to pipeline and label expansion efforts are eagerly awaited by investors in the biotech/pharma space as these play a crucial role in their investment decisions. These updates provide ...
GlaxoSmithKline and the FDA notified healthcare professionals of a new safety finding in patients with thrombocytopenia due to chronic liver disease treated with Promacta (eltrombopag tablets). The ...
Promacta is available in both tablet and liquid suspension forms, with dosages varying based on the specific blood disorder being treated. But, it’s typically taken once per day. When taking Promacta, ...
First supportive care treatment approved for patients with thrombocytopenia with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy LONDON, Nov. 19, 2012 ...
Recently, the FDA granted a breakthrough therapy designation to eltrombopag (Promacta, Novartis) for combination use with standard immunosuppressive therapy as a first-line treatment for patients with ...
"PROMACTA is the first approved agent to show that generating platelets can be achieved and maintained with an oral therapy," said Paolo Paoletti, M.D., Senior Vice President of Oncology R&D, GSK.
(HealthDay)—U.S. Food and Drug Administration approval of the drug Promacta (eltrombopag) has been expanded to include children one year and older with a rare blood disorder called chronic immune ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA granted priority review ...
The company is recalling the lots because of possible peanut flour contamination. Novartis announced on May 11, 2019 that it was recalling three lots of Promacta (eltrombopag) 12.5 mg for oral ...
PHILADELPHIA, Dec. 6 GlaxoSmithKline (NYSE: GSK)announced positive safety and efficacy results from RAISE (RAndomized placebo-controlled ITP Study with Eltrombopag), a Phase III study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results